Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Pediatrics, Pediatric Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Blood Adv. 2024 Jun 11;8(11):2753-2764. doi: 10.1182/bloodadvances.2023012385.
Despite the global unrelated donor (URD) registry size, the degree to which URD availability is a transplant barrier is not established. We evaluated the availability of 3,843 URDs requested for 455 diverse adult patients (predominantly with acute leukemia). URDs for non-Europeans were more likely to be domestic and had markedly lower Donor Readiness scores. Of URDs requested for confirmatory HLA-typing (CT) alone (ie, without simultaneous workup), 1,894 of 3,529 (54%) were available. Availability of domestic URDs was 45%. Donor Readiness score was highly predictive of CT availability. More non-European patients (n = 120) than Europeans (n = 335) had >10 URDs requested and <5 available. Of workup requests (after CT or CT-workup), <70% (604/889 [68%]) were available. More non-Europeans had <2 URDs available. URD availability for CT was markedly worse for non-Europeans, with availabilities for African, non-Black Hispanic, and Asian patients being 150/458 (33%), 120/258 (47%), and 119/270 (44%), respectively, with further decrements in URD workup availability. Our data suggest the functional size of the URD pool is much smaller than appreciated, mandating major operational changes for transplant centers and donor registries. Likelihood of donor availability should have a high priority in donor selection. Considering patient ancestry and URD Donor Readiness scores, centers should pursue, and registries permit, simultaneous pursuit of many URDs and abandon futile searches. Patients should be informed about their likelihood of donor availability and alternative options. Finally, although registries should address high URD attrition and speed procurement, use of all HLA-disparate graft types is needed to facilitate timely transplant for all.
尽管全球有非亲属供者(URD)登记库,但 URD 可用性是否构成移植障碍尚不确定。我们评估了为 455 名不同成年患者(主要为急性白血病患者)申请的 3843 名 URD 的可用性。非欧洲裔患者的 URD 更有可能来自国内,且供者准备度评分明显较低。在仅申请确认 HLA 配型(CT)的 URD 中(即,无同时进行的检查),3529 名 URD 中的 1894 名(54%)是可用的。国内 URD 的可用性为 45%。供者准备度评分对 CT 的可用性有高度预测性。与欧洲患者(n=335)相比,有更多的非欧洲患者(n=120)申请了>10 名 URD 但仅有<5 名 URD 可用。在检查(CT 后或 CT 检查后)申请中,<70%(604/889 [68%])是可用的。非欧洲裔患者的 URD 可用性<2 名。非欧洲裔患者的 CT 用 URD 可用性明显更差,非洲、非黑西班牙裔和亚洲患者的 URD 可用性分别为 150/458(33%)、120/258(47%)和 119/270(44%),而 URD 检查可用性进一步下降。我们的数据表明,URD 库的实际规模比预期的要小得多,这需要移植中心和供者登记处进行重大运营变革。供者可用性的可能性应在供者选择中具有较高优先级。考虑到患者的祖源和 URD 供者准备度评分,中心应同时追求并允许同时追求多个 URD,并放弃无效的搜索。应告知患者其供者可用性的可能性和替代方案。最后,尽管登记处应解决 URD 大量流失和加快采购速度,但需要使用所有 HLA 不相容的移植物类型,以促进所有患者的及时移植。